KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Inventory: 2011-2024

Historic Change in Inventory for Regeneron Pharmaceuticals (REGN) over the last 14 years, with Dec 2024 value amounting to $619.7 million.

  • Regeneron Pharmaceuticals' Change in Inventory fell 49.76% to $82.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $395.1 million, marking a year-over-year decrease of 28.07%. This contributed to the annual value of $619.7 million for FY2024, which is 128.08% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Change in Inventory of $619.7 million as of FY2024, which was up 128.08% from $271.7 million recorded in FY2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Change in Inventory peaked at $696.5 million during FY2022, and registered a low of $271.7 million during FY2023.
  • Its 3-year average for Change in Inventory is $529.3 million, with a median of $619.7 million in 2024.
  • Its Change in Inventory has fluctuated over the past 5 years, first slumped by 60.99% in 2023, then skyrocketed by 128.08% in 2024.
  • Regeneron Pharmaceuticals' Change in Inventory (Yearly) stood at $529.4 million in 2020, then fell by 6.63% to $494.3 million in 2021, then surged by 40.91% to $696.5 million in 2022, then tumbled by 60.99% to $271.7 million in 2023, then surged by 128.08% to $619.7 million in 2024.